Publication:
The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: -A Single-Center Experience-

Thumbnail Image
Files
IMJ-22-133-En.pdf (246.64 KB)
Date
2021-05-01T00:00:00Z
Authors
Authors
ESER, ALİ
Timuragaoglu, Aysen
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
Introduction: High-dose chemotherapy fol lowed by autologous stem cell transplantation (ASCT) is the standard treatment for relapsed and refractory lymphoma patients. The difficulties in accessing and high cost of carmustine have led to the increased use of alternative regimen before ASCT for the treatment of lymphoma, including busulfan-based busulfan-etoposidemelphalan (BuEM) regimens.
Description
Keywords
Citation
ESER A., Timuragaoglu A., -The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: -A Single-Center Experience-, ISTANBUL MEDICAL JOURNAL, cilt.22, sa.2, ss.133-139, 2021
URI
http://hdl.handle.net/20.500.12645/28917
Collections
Yayınlar - Eserler
TR Dizin İndeksli Yayınlar Koleksiyonu
Page Views

0

File Downloads

6

Sustainable Development Goals